 |
5 Diseases |  |
7 Trials |
|
7 Trials |  |
708 News |  |
| «123456789 |
- avacopan (CCX168) / Kissei, Vifor, ChemoCentryx
Evaluating the Efficacy and Safety of C5aR Inhibitor Avacopan (CCX168) in Patients with Complement 3 Glomerulopathy: A Randomized, Double Blind, Placebo-Controlled Phase 2 Study (Exhibit Hall, Walter E. Washington Convention Center) - Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4507;
P2
The data from this study will inform on the effects of 26 and 52 weeks of treatment with avacopan on the C3G Histologic Index as assessed by renal biopsy and on reduction in proteinuria as measured by UPCR as compared to placebo.
- | avacopan (CCX168) / Kissei, Galenica, ChemoCentryx, PMX 53 / Teva
Journal: Orthosteric and allosteric action of the C5a receptor antagonists. (Pubmed Central) - Aug 28, 2019
We also discuss critical structural features of C5aR in activation, including a novel conformation of helix 8. On the basis of our results, we suggest novel strategies for developing C5aR-targeting drugs.
- |||| Tavneos (avacopan) / Kissei, Amgen, Otsuka
Trial primary completion date: ADVOCATE: A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (clinicaltrials.gov) - Jul 5, 2019
P3, N=300, Active, not recruiting, Sponsor: ChemoCentryx
On the basis of our results, we suggest novel strategies for developing C5aR-targeting drugs. Trial primary completion date: Jun 2019 --> Sep 2019
- || Tavneos (avacopan) / Amgen
Trial completion date, Trial primary completion date: ACCOLADE: Controlled Trial Evaluating Avacopan in C3 Glomerulopathy (clinicaltrials.gov) - Jun 18, 2019
P2, N=88, Recruiting, Sponsor: ChemoCentryx
Trial primary completion date: Jun 2019 --> Sep 2019 Trial completion date: Oct 2019 --> Dec 2020 | Trial primary completion date: Feb 2019 --> Dec 2019
- | Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Biogen
Journal: Vasculitis research: Current trends and future perspectives. (Pubmed Central) - May 29, 2019
Increasingly, the risk of cardiovascular events and comorbidities such as osteoporosis are being recognized as factors affecting long-term prospects of patients with vasculitis. There is a shift in emphasis to utilize patient-reported outcomes to more accurately gauge the impact of vasculitides and their treatment.
- | Campath (alemtuzumab) / Sanofi, Rituxan (rituximab) / Roche, Biogen
Biomarker, Journal: Novel trends in monitoring and therapy of ANCA associated vasculitides (Pubmed Central) - May 11, 2019
In modern biological therapy rituximab is widely used, for refractory cases intravenous immunoglobulins and antithymocyte globulin are recommended. The data from clinical trials with alemtuzumab are controversial, but avacopan selective inhibitor of C5a receptor and inhibitor of B-lymphocyte activation factor belimumab are promise for future.Key words: biologicals - biomarkers - eosinophilic granulomatosis with polyangiitis - granulomatosis with polyangiitis - microscopic polyangiitis.
- |||| avacopan (CCX168) / Kissei, Galenica, ChemoCentryx
ANCA Associated Vasculitis: Treatment with Avacopan #VisualAbstract by @kidney_boy #NKFClinicals 🇺🇸 #Nephpearls 👉🏼 https://t.co/GZWYoPVhd6 (Twitter) - May 8, 2019
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, Journal: Allergology and clinical immunology (Pubmed Central) - Apr 30, 2019
In giant cell arteritis, the use of tocilizumab in conjunction with low doses of GC reduces the number of relapses. In ANCA-associated vasculitis the use of an anti-C5R (avacopan) alone or in conjunction with low doses of GC results in similar remission rates to those induced by high dose GC.
- ||||| Tavneos (avacopan) / Amgen
New P2 trial: Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA) (clinicaltrials.gov) - Feb 25, 2019
P2, N=390, Recruiting, Sponsor: ChemoCentryx
- ||||| Tavneos (avacopan) / Kissei, Amgen, Otsuka
Enrollment closed: ADVOCATE: A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (clinicaltrials.gov) - Sep 20, 2018
P3, N=300, Active, not recruiting, Sponsor: ChemoCentryx
In ANCA-associated vasculitis the use of an anti-C5R (avacopan) alone or in conjunction with low doses of GC results in similar remission rates to those induced by high dose GC. Recruiting --> Active, not recruiting
- || Tavneos (avacopan) / Amgen
Enrollment change: ACCOLADE: Controlled Trial Evaluating Avacopan in C3 Glomerulopathy (clinicaltrials.gov) - Jun 6, 2018
P2, N=88, Recruiting, Sponsor: ChemoCentryx
Recruiting --> Active, not recruiting N=44 --> 88
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
Trial primary completion date: ACCESS: Complement Inhibition in aHUS Dialysis Patients (clinicaltrials.gov) - Nov 14, 2017
P2, N=6, Terminated, Sponsor: Mario Negri Institute for Pharmacological Research
N=44 --> 88 Trial primary completion date: Feb 2017 --> Jul 2017
- | Tavneos (avacopan) / Amgen
New P2 trial: ACCOLADE: Controlled Trial Evaluating Avacopan in C3 Glomerulopathy (clinicaltrials.gov) - Oct 4, 2017
P2, N=44, Recruiting, Sponsor: ChemoCentryx
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
Enrollment change, Trial termination: ACCESS: Complement Inhibition in aHUS Dialysis Patients (clinicaltrials.gov) - Mar 3, 2017
P2, N=6, Terminated, Sponsor: Mario Negri Institute for Pharmacological Research
Trial primary completion date: Feb 2017 --> Jul 2017 N=10 --> 6 | Recruiting --> Terminated; The study had accomplished its goal with the 6 patients who have been enrolled.
- |||| Tavneos (avacopan) / Kissei, Amgen
P3 data: ADVOCATE: A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (clinicaltrials.gov) - Jan 14, 2017
P3, N=300, Recruiting, Sponsor: ChemoCentryx
N=10 --> 6 | Recruiting --> Terminated; The study had accomplished its goal with the 6 patients who have been enrolled. Trial primary completion date: Dec 2019 --> Jun 2019
- |||||| Tavneos (avacopan) / Kissei, Amgen, Otsuka
Enrollment open: ADVOCATE: A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (clinicaltrials.gov) - Jan 14, 2017
P3, N=300, Recruiting, Sponsor: ChemoCentryx
Trial primary completion date: Dec 2019 --> Jun 2019 Not yet recruiting --> Recruiting
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
Trial completion: Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade (clinicaltrials.gov) - Dec 20, 2016
P2, N=5, Completed, Sponsor: ChemoCentryx
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Tavneos (avacopan) / Kissei, Amgen
P3 data: ADVOCATE: A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (clinicaltrials.gov) - Dec 15, 2016
P3, N=300, Not yet recruiting, Sponsor: ChemoCentryx
- | Tavneos (avacopan) / Kissei, Amgen, Otsuka
Trial completion: Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis (clinicaltrials.gov) - Nov 16, 2016
P2, N=42, Completed, Sponsor: ChemoCentryx
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
Trial primary completion date: ACCESS: Complement Inhibition in aHUS Dialysis Patients (clinicaltrials.gov) - Jun 9, 2016
P2, N=10, Recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Jan 2017
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
Enrollment closed, Enrollment change: Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade (clinicaltrials.gov) - Feb 9, 2016
P2, N=5, Active, not recruiting, Sponsor: ChemoCentryx
Trial primary completion date: May 2016 --> Jan 2017 Recruiting --> Active, not recruiting | N=20 --> 5
- | Tavneos (avacopan) / Kissei, Amgen, Otsuka
Enrollment closed: Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis (clinicaltrials.gov) - Feb 3, 2016
P2, N=42, Active, not recruiting, Sponsor: ChemoCentryx
Recruiting --> Active, not recruiting | N=20 --> 5 Recruiting --> Active, not recruiting
- |||| Tavneos (avacopan) / Amgen
Trial completion: A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis (clinicaltrials.gov) - Jan 21, 2016
P2, N=67, Completed, Sponsor: ChemoCentryx
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Tavneos (avacopan) / Amgen
Enrollment closed: A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis (clinicaltrials.gov) - Aug 19, 2015
P2, N=60, Active, not recruiting, Sponsor: ChemoCentryx
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
New P2 trial: ACCESS: Complement Inhibition in aHUS Dialysis Patients (clinicaltrials.gov) - Jun 6, 2015
P2, N=10, Recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
Trial primary completion date: Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade (clinicaltrials.gov) - Apr 19, 2015
P2, N=20, Recruiting, Sponsor: ChemoCentryx
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Sep 2016
- | Tavneos (avacopan) / Kissei, Amgen, Otsuka
New P2 trial: Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade (clinicaltrials.gov) - Mar 10, 2015
P2, N=20, Recruiting, Sponsor: ChemoCentryx
- | Tavneos (avacopan) / Kissei, Amgen, Otsuka
Enrollment open: Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis (clinicaltrials.gov) - Jan 7, 2015
P2, N=45, Recruiting, Sponsor: ChemoCentryx
Trial primary completion date: Jun 2016 --> Sep 2016 Not yet recruiting --> Recruiting
- | Tavneos (avacopan) / Kissei, Amgen, Otsuka
New P2 trial: Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis (clinicaltrials.gov) - Aug 21, 2014
P2, N=45, Not yet recruiting, Sponsor: ChemoCentryx
- |||| Tavneos (avacopan) / Amgen
Enrollment open: A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis (clinicaltrials.gov) - Aug 28, 2011
P2, N=60, Recruiting, Sponsor: ChemoCentryx
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting